Myomo, Inc.


MYO

NYSE; healthcare; SIC 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies; CIK 0001369290

B/C

on the B/C boundary of 370 graded peers in healthcare

rank 152 of 370; percentile 40.9; sampling error 2.5 points; lower is stronger



B/C, the elk




Scoreboard	
Profitability	C percentile 47.4
Solvency	D percentile 62.8
Growth and financing	B percentile 25.9
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $38.6M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet
Inputs computable	9 of 14
Graded from	filings received through Apr 29, 2026 180 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	$1.22 2026-10-23; market equity $48.3M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 9, 2026

We are a wearable medical robotics company that offers functional improvement for those with neuromuscular disorders and upper limb paralysis. We develop and market the MyoPro product line. A MyoPro is a myoelectric-controlled upper limb brace, or orthosis. The orthosis is a rigid brace used for the purpose of supporting a patient's weak or paralyzed arm to enable and help improve functional activities of daily living, or ADLs, in the home and community. It is custom-fabricated by trained professionals during a custom fabrication process for each individual user to meet their specific needs.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 47.4						
Gross profitability	69.6%	32.3%		11.7	368	2025-12-31
Return on invested capital	not computable	9.3%				

a prior annual debt, equity, and cash observation is required

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(2.6%)	(6.6%)	73.0	807	2025-12-31
Gross margin stability, five years	3.3 pts	2.8 pts	57.7	242	2025-12-31
Solvency, sleeve percentile 62.8					
Twelve-month failure probability	0.27%	0.07%	74.5	248	2026-06-30
Altman Z double-prime	(8.82)	(0.33)	59.8	752	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	3.30x	2.94x	54.0	834	2025-12-31
Growth and financing, sleeve percentile 25.9					
Revenue growth, three-year compound	38.1%	10.1%	17.7	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	56.1%	2.1%	6.7	700	2025-12-31
Net share issuance, one year	12.0%	2.5%	53.4	636	2026-03-02


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 2,909,872 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
147	UroGen Pharma Ltd. (URGN)	39.6	B/C	short runway
148	National Healthcare Corp. (NHC)	39.8	B/C	fortress balance sheet
149	Shattuck Labs, Inc. (STTK)	40.1	B/C	dilution
150	ImmunityBio, Inc. (IBRX)	40.4	B/C	short runway
151	Celldex Therapeutics, Inc. (CLDX)	40.7	B/C	short runway
152	Myomo, Inc. (MYO)	40.9	B/C	fortress balance sheet
153	Lifevantage Corp. (LFVN)	41.2	B/C	
154	Xeris Biopharma Holdings, Inc. (XERS)	41.5	B/C	
155	Envista Holdings Corp. (NVST)	41.7	B/C	
156	Sight Sciences, Inc. (SGHT)	42.0	B/C	fortress balance sheet
157	Repligen Corp. (RGEN)	42.3	B/C	late filer, fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	67.0%	7.7%	82
Distance from 52-week high	(34.9%)	(31.4%)	43
EBIT to enterprise value	(29.9%)	(1.5%)	20
Free cash flow yield	(33.9%)	(1.0%)	18
Book value to price	0.12	0.28	31
Sales to price	0.85	0.30	79
Composite equity issuance, five years	195.9%	20.5%	89
Relative strength against the sector, log excess return	0.30	(0.14)	82

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$11.2M
Operating cash flow, four quarters	-$7.1M
Months of runway	18.9
Days since last periodic filing	82 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	$497,334

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$26.9M	2025-12-31	2026-03-09	10-K	26-098531
2	assets	us-gaap:Assets	$38.6M	2025-12-31	2026-03-09	10-K	26-098531
3	operating income	us-gaap:OperatingIncomeLoss	-$14.4M	2025-12-31	2026-03-09	10-K	26-098531
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$15.1M	2025-12-31	2026-03-09	10-K	26-098531
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$504,532	2025-12-31	2026-03-09	10-K	26-098531
6	total debt	us-gaap:LongTermDebt	$11.2M	2025-12-31	2026-03-09	10-K	26-098531
7	book equity	us-gaap:StockholdersEquity	$11.4M	2025-12-31	2026-03-09	10-K	26-098531
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$14.1M	2025-12-31	2026-03-09	10-K	26-098531
9	net income	us-gaap:NetIncomeLoss	-$15.6M	2025-12-31	2026-03-09	10-K	26-098531
10	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$14.5M	2025-12-31	2026-03-09	10-K	26-098531
11	assets	us-gaap:Assets	$42.2M	2024-12-31	2026-03-09	10-K	26-098531
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$40.9M	2025-12-31	2026-03-09	10-K	26-098531
13	gross profit	us-gaap:GrossProfit	$23.2M	2024-12-31	2026-03-09	10-K	26-098531
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$32.6M	2024-12-31	2026-03-09	10-K	26-098531
15	gross profit	us-gaap:GrossProfit	$13.2M	2023-12-31	2025-03-10	10-K	25-036349
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$19.2M	2023-12-31	2025-03-10	10-K	25-036349
17	gross profit	us-gaap:GrossProfit	$10.3M	2022-12-31	2024-03-08	10-K	24-028326
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$15.6M	2022-12-31	2024-03-08	10-K	24-028326

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	gross profit	us-gaap:GrossProfit	$10.3M	2021-12-31	2023-03-13	10-K	23-007560
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$13.9M	2021-12-31	2023-03-13	10-K	23-007560
21	current assets	us-gaap:AssetsCurrent	$27.6M	2025-12-31	2026-03-09	10-K	26-098531
22	current liabilities	us-gaap:LiabilitiesCurrent	$8.3M	2025-12-31	2026-03-09	10-K	26-098531
23	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$118.7M	2025-12-31	2026-03-09	10-K	26-098531
24	liabilities	us-gaap:Liabilities	$27.2M	2025-12-31	2026-03-09	10-K	26-098531
25	depreciation amortization	us-gaap:Depreciation	$859,354	2025-12-31	2026-03-09	10-K	26-098531
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.7M	2025-12-31	2026-03-09	10-K	26-098531
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$3.3M	2024-12-31	2026-03-09	10-K	26-098531
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.4M	2024-12-31	2026-03-09	10-K	26-098531
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$6.2M	2023-12-31	2025-03-10	10-K	25-036349
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$145,816	2023-12-31	2025-03-10	10-K	25-036349
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$10.2M	2022-12-31	2024-03-08	10-K	24-028326
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$111,793	2022-12-31	2024-03-08	10-K	24-028326
33	current assets	us-gaap:AssetsCurrent	$32.8M	2024-12-31	2026-03-09	10-K	26-098531
34	current liabilities	us-gaap:LiabilitiesCurrent	$10.2M	2024-12-31	2026-03-09	10-K	26-098531
35	assets	us-gaap:Assets	$14.6M	2023-12-31	2025-03-10	10-K	25-036349
36	assets	us-gaap:Assets	$10.2M	2022-12-31	2024-03-08	10-K	24-028326
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	38,511,715	2026-03-02	2026-04-29	10-K/A	26-191496
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	34,381,125	2025-03-01	2025-03-10	10-K	25-036349

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.